期刊文献+

系统性硬化病相关肺动脉高压的临床特点 被引量:4

The clinical characteristics of systemic sclerosis-related pulmonary arterial hypertension
原文传递
导出
摘要 目的 通过对比系统性硬化病(SSc)相关肺动脉高压(PAH)和特发性肺动脉高压(IPAH)的临床资料,进一步明确SSc相关PAH的临床特点.方法 入选经右心导管确诊并除外其他疾病的SSc相关PAH者和IPAH者,比较其临床资料、6分钟步行距离(6MWD)、肺功能及血流动力学参数.结果 SSc相关PAH者20例,女19例,男1例,年龄(43.1 ±12.2)岁;IPAH者18例,女16例,男2例,年龄(38.4±12.4)岁.两者平均肺动脉压、心指数和肺血管阻力(PVR)差异无统计学意义.与IPAH者比,SSc相关PAH者的用力肺活量(FVC)占预计值百分比[(77.1±13.2)%比(88.6±14.9)%,P=0.026]、肺一氧化碳弥散量(DLCO)占预计值百分比[(46.2±13.1)%比(66.6±13.3)%,P<0.001]、[DLCO/肺泡通气量(VA)]占预计值百分比[(55.1±14.3)%比(75.1±11.5)%,P<0.001]降低,6MWD缩短[(365.6 ±85.1)m比(454.3±136.8)m,P=0.034].多因素分析显示,PVR升高(OR=2.122,95% CI1.093 ~4.119,P=0.026)、DLCO占预计值百分比降低(OR=0.916,95% CI0.842~0.996,P=0.040)是6MWD <400 m的独立预测因素.结论 在血流动力学参数相同的情况下,SSc相关PAH者的限制性通气障碍和弥散障碍较IPAH者更为多见. Objective To study the clinical,cardiopulmonary functional and hemodynamic profiles of systemic sclerosis patients with pulmonary hypertension (SSc-PAH) compared with those of idiopathic pulmonary hypertension (IPAH).Methods Patients diagnosed with SSc-PAH or IPAH by right heart catheterization were consecutively enrolled into the study between 2011 and 2013 in Peking Union Medical College Hospital (PUMCH).Cases with pulmonary hypertension related to other diseases were excluded.Demographic data,laboratory parameters,6 minutes walk distance (6MWD),pulmonary function and hemodynamic variables at the time of diagnosis were collected and compared between the two groups.Results A total of 20 SSc-PAH patients including 19 females and one male with age of (43.1 ± 12.2) years,and 18IPAH patients including 16 females and 2 males with age of (38.4 ± 12.4) years were enrolled in this study.Subjects in both groups had similar mean pulmonary arterial pressure,cardiac index and pulmonary vascular resistance (PVR) when recruited.Compared with IPAH patients,SSc-PAH patients showed significantly decreased all parameters including forced vital capacity (FVC)% [(77.1 ± 13.2)% vs (88.6 ± 14.9)%,P =0.026],diffusing capacity of the lung for carbon monoxide (DLCO) % [(46.2 ±13.1) % vs (66.6± 13.3)%,P <0.001],DLCO/alveolar ventilation(VA) [(55.1 ± 14.3)% vs (75.1 ± 11.5)%,P <0.001],and 6MWD [(365.6 ±85.1) m vs (454.3 ± 136.8) m,P =0.034].In subgroup analysis of SSc-PAH patients,elevated PVR (OR 2.122,95% CI 1.093-4.119,P =0.026) and decreased DLCO% (OR 0.916,95% CI 0.842-0.996,P =0.040) were independently associated with reduced 6MWD.Conclusions Under the similar hemodynamic condition,SSc-PAH patients had more severe restrictive ventilation dysfunction and diffusion capacity dysfunction.Decreased 6MWD in SSc-PAHpatients was probably related to the impairment of pulmonary function.
出处 《中华内科杂志》 CAS CSCD 北大核心 2014年第5期390-393,共4页 Chinese Journal of Internal Medicine
基金 欧洲抗风湿病联盟硬皮病试验研究组项目 国家科技重大专项(2012ZX09303006-002) 国家“十二五”科技支撑计划课题(2011BAI11B15) 国家自然科学基金(81072485、81071300、81102268) 卫生公益性行业科研专项(201202004) 首都医学发展科研基金重点支持项目(2009-2003)
关键词 高血压 肺性 硬皮病 系统性 呼吸功能试验 血流动力学 Hypertension, pulmonary Scleroderma, systemic Respiratory function test Hemodynamics
  • 相关文献

参考文献12

  • 1McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc. , and the Pulmonary Hypertension Association [ J ]. Circulation, 2009, 119,2250-2294.
  • 2Overbeek MJ, Vonk MC, Boonstra A, et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy[ J ]. Eur Respir J, 2009, 34:371-379.
  • 3Clements PJ, Tan M, McLaughlin VV, et al. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH [ J ]. Ann Rheum Dis, 2012, 71:249-252.
  • 4Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension[ J]. Arthritis Rheum, 2006, 54:3043-3050.
  • 5ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six- minute walk test[ J]. Am J Respir Crit Care Med, 2002, 166: 111-117.
  • 6全国eGFR课题协作组.MDRD方程在我国慢性肾脏病患者中的改良和评估[J].中华肾脏病杂志,2006,22(10):589-595. 被引量:702
  • 7Le Pavec J, Launay D, Mathai SC, et al. Scleroderma lung disease [ J ]. Clin Rev Allergy Immunol, 2011, 40 : 104-116.
  • 8Sun XG, Hansen JE, Oudiz R J, et al. Pulmonary function in primary pulmonary hypertension [ J ]. J Am Coil Cardiol, 2003, 41:1028-1035.
  • 9Launay D, Humbert M, Berezne A, et al. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease [ J ]. Chest, 2011, 140 : 1016-1024.
  • 10Fischer A, Bull TM, Steen VD. Practical approach to screening for scleroderma-associated pulmonary arterial hypertension [ J ]. Arthritis Care Res ( Hoboken), 2012,64:303-310.

二级参考文献21

  • 1Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem, 1992,38 : 1933-1953.
  • 2Giovannetti S, Barsotti G. In defense of creatinine clearance.Nephron, 1991,59: 11-14.
  • 3Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med,1999,130:461-470.
  • 4Levey AS, Greene T, Kusek J, et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol, 2000, 11 : A0828 (abstract).
  • 5Eknoyaa G, Levin N. NKF-K/DOQI Clinical Practice Guidelines: Update 2000. Foreword. Am J Kidney Dis,2001, 37 (1 Suppl 1):S5-S6. Erratum in: Am J KidneyDis, 2001,38:917.
  • 6Zuo L, Ma YC, Zhou YH, et al. Application of GFR-estimating equations in Chinese patients with chronic kidney disease. Am .I Kidney Dis, 2005, 45:463-472.
  • 7Blaufox MD, Aurell M, Bubeck B, et al. Report of the Radionuclides in Nephrourology Committee on renal clearance.J Nucl Med, 1996, 37:1883-1890.
  • 8Chantler C, Barratt TM. Estimation of glomerular filtration rate from plasma clearance of 51-chromium edetic acid. Arch Dis Child, 1972, 47:613-617.
  • 9Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known.1916. Nutrition, 1989,5 : 303-311.
  • 10Duan N.Smearing estimate:a nonparametric retransformation method. Journal of the American Statistical Association,1983, 78 : 605-610.

共引文献701

同被引文献37

  • 1Chung L,Liu J,Parsons L,et al.Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL.Identifying systemic sclerosis as a unique phenotype[J].Chest,2010,138 (6):1383-1394.
  • 2Condliffe R,Kiely DG,Peacock AJ,et al.Connective tissue disease-associated pulmonary arterial hypertension in the modem treatment era[J].Am J Respir Crit Care Med,2009,179(2):151-157.
  • 3Yang X,Mardekian J,Sanders KN,et al.Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases:a systematic review of the literature[J].Clin Rheumatol,2013,32 (10):1519-1531.
  • 4Olschewski H,Simonneau G,Galie N,et al.Inhaled iloprost for severe pulmonary hypertension[J].N Engl J Med,2002,347 (5):322-329.
  • 5Rubin LJ,Badesch DB,Barst R J,et al.Bosentan therapy for pulmonary arterial hypertension[J].N Engl J Med,2002,346(12):896-903.
  • 6Sanchez O,Sitbon O,Jais X,et al.Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension[J].Chest,2006,130 (1):182-189.
  • 7Lefèvre G,Dauchet L,Hachulla E,et al.Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension:a systematic review and meta-analysis[J].Arthritis Rheum,2013,65 (9):2412-2423.
  • 8Mathai SC,Hummers LK,Champion HC,et al.Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases:impact of interstitial lung disease[J].Arthritis Rheum,2009,60 (2):569-577.
  • 9Hao Y J,Jiang X,Zhou W,et al.Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients[J].Eur Respir J,2014 May 2.[Epub ahead of print].
  • 10Simonson JS,Schiller NB,Petri M,et al.Pulmonary hypertension in systemic lupus erythematosus[J].J Rheumatol,1989,16 (7):918-925.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部